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Abstract 
 
Captan and folpet are fungicides largely used in agriculture. They have similar chemical 
structures, except that folpet has an aromatic ring unlike captan. Their half-lives in blood are very 
short, given that they are readily broken down to tetrahydrophthalimide (THPI) and phthalimide 
(PI), respectively. Few authors measured these biomarkers in plasma or urine and analysis was 
conducted either by gas chromatography coupled to mass-spectrometry (GC-MS) or liquid 
chromatography with UV detection (LC-UV). The objective of this study was thus to develop 
simple, sensitive and specific liquid chromatography - atmospheric pressure chemical ionization-
tandem mass spectrometry (LC/APCI-MS/MS) methods to quantify both THPI and PI in human 
plasma and urine. Briefly, deuterated THPI was added as an internal standard and purification 
was performed by solid phase extraction followed by LC/APCI-MS/MS analysis in negative ion 
mode for both compounds. Validation of the methods was conducted using spiked blank plasma 
and urine samples at concentrations ranging from 1 to 250 µg/L and 1 to 50 µg/L, respectively, 
along with samples of volunteers exposed to captan or folpet. The methods showed a good 
linearity (R
2 
> 0.99), recovery (on average 90% for THPI and 75% for PI), intra- and inter-day 
precision (RSD < 15%) and accuracy (< 20%), and stability. The limit of detection was 0.58 µg/L 
in urine and 1.47 µg/L in plasma for THPI, and 1.14 and 2.17 µg/L, respectively, for PI. The 
described methods proved to be accurate and suitable to determine the toxicokinetics of both 
metabolites in human plasma and urine. 
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Introduction 
 
Many winegrowers and tree farmers apply captan (1,2,3,6-tetrahydro-N-(trichloromethyl thio) 
phthalimide) or folpet (N-(trichloromethyl thio) phthalimide) to treat fungal diseases. These two 
common fungicides belong to the family of thiophthalimide pesticides. They have a very similar 
chemical structure, except that folpet has an aromatic ring while captan has a cyclohexene ring. 
Both compounds have very short half-lives in biological matrices, as assessed by Gordon et al. 
[1;2]. Captan was found to degrade with a half-life of 0.97 seconds in blood and folpet with a 
half-life of 4.9 seconds when 14C-captan was directly added at 33.2 nmol/L and 14C-folpet at 33.7 
nmol/L to 1 mL of human blood [1]. Therefore, they are almost instantaneously metabolized to 
tetrahydrophtalimide (THPI) for captan and to phthalimide (PI) for folpet (Fig. 1). Unlike the two 
parent compounds, THPI and PI metabolites can be quantified in human plasma and urine [3-12]. 
Other metabolites of captan and folpet have also been identified in animal metabolism studies, 
namely 2-thiothiazolidine-4-carboxyl acid (TTCA) as a trichloromethyl thio derivative metabolite 
of captan, THPI derivatives, and phthalamic and phthalic acids as derivatives of PI [2;13-16]; 
nonetheless, THPI is the metabolite of captan most measured in the published human 
biomonitoring studies [5-12] while human biomonitoring data on the metabolites of folpet are 
limited [3;17]. 
 
The published analytical methods for the measurement of THPI and PI in human plasma or urine 
used either gas chromatography with mass spectrometry detection (GC-MS) [3;6;7;10] or liquid 
chromatography with UV detection (LC-UV) [4]. Liquid chromatography – mass spectrometry 
(LC-MS) methods with atmospheric pressure chemical ionization (APCI) have yet to be 
developed for these biomarkers. LC-APCI-MS analysis is known to be very specific to one 
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analyte and to improve sensitivity, especially for the detection of more polar or low-concentration 
compounds [18]. The objective of this work was thus to develop such analytical methods for the 
quantification of THPI and PI in human plasma and urine to determine the toxicokinetics of these 
biomarkers in volunteers as well as assess worker exposure to captan and folpet through 
biomonitoring. 
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Materials and methods 
 
Chemicals and reagents 
Reference standards of cis-1,2,3,6-tetrahydrophthalimide (THPI) and phthalimide (PI) (>99% 
purity) were obtained from Sigma-Aldrich (Buchs, St Gallen, Switzerland), while deuterated cis-
1,2,3,6-tetrahydrophthalimide (THPI-d) (99% purity) was purchased from Cambridge Isotope 
Laboratories Inc. (Andover, MA, USA). HPLC grade acetonitrile, methanol and dichloromethane 
were also obtained from Sigma-Aldrich (Buchs, St Gallen, Switzerland). Ammonium sulphate 
was purchased from Merck (Zug, Switzerland). Water was purified using a TKA GenPure water 
treatment system obtained from TKA Wasseraufbereitungsszsteme GmbH (Niederelbert, 
Germany). 
 
Standard preparation 
Stock standard solutions 
Individual stock standard solutions were prepared by dissolving 100 mg of THPI or PI in 100 mL 
of methanol and 20 mg of THPI-d in 100 mL of methanol. They were stored at -20° C in a glass 
container until used. 
 
Calibration curves 
To prepare the calibration curves, stock standard solutions were diluted to obtain working 
solutions of THPI and PI standards at 10, 100, and 1 000 mg/L. These working standard solutions 
were kept at 4°C and were used daily to prepare calibration curves in urine and plasma, hence to 
spike blank urine from nonexposed persons at six concentration levels and blank plasma from 
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nonexposed persons at six concentration levels. The concentration levels were the same for both 
THPI and PI, thus 0.5, 1, 2, 5, 10 and 50 µg/L in urine and 1, 5, 10, 50, 100 and 250 µg/L  in 
plasma. 
 
Similarly, the stock internal standard solution was diluted to obtain a working solution at 250 
µg/L. A constant volume of 125 µL of this solution was added to the calibration curve samples, 
which translates into a concentration of 62.5 µg/L in the 500 µL urinary and plasma extracts after 
sample processing. 
 
Simultaneously, calibration points were also prepared in methanol from the same working 
solutions of THPI, PI and THPI-d standards. The six concentration levels were 1, 2, 5, 10, 15 and 
20 µg/L for THPI and PI. Since final volume of each level was 1 ml, 250 µL of THPI-d working 
solution at 250 µg/L were thus added in this case, which corresponds to a concentration of 62.5 
µg/L. 
 
Sample treatment 
Analysis of THPI and PI in urine 
THPI and PI in urine were analyzed using liquid chromatography - atmospheric pressure 
chemical ionization-tandem mass spectrometry (LC/APCI-MS/MS) methods, after solid phase 
extraction (SPE). More specifically, 3-mL aliquots of urine of exposed individuals (workers or 
volunteers) along with that of non-occupationally exposed subjects were transferred into glass 
tubes and spiked with 125 µL of THPI-d internal standard (250 µg/L). Extraction of THPI and PI 
was then performed using Oasis® SPE cartridges (Waters, Montreux, Switzerland). The 
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cartridges were first conditioned with 8 mL of dichloromethane, followed by 8 mL of methanol 
and 12 mL of water. The urines were passed through the column and discarded. The cartridges 
were washed with 1.5 mL of 5% methanol: 95% water (v/v) and left to dry for 15 min under 
vacuum (10 inHg). The analytes were then eluted from the column with 4 mL of dichloromethane 
into 5 mL glass tubes. The solvent was evaporated to dryness under a gentle nitrogen flow at 
40°C. The residues were resuspended in 500 µL of methanol and transferred to vials for 
LC/APCI-MS/MS analysis. 
 
Analysis of THPI and PI in plasma 
Analysis of THPI and PI in blood of exposed individuals was performed as described for urine, 
except that a 2-mL aliquot of plasma was used and a step for the denaturation of proteins was 
added, prior to SPE extraction. This step consisted of adding 4 mL of saturated ammonium 
sulphate to the plasma sample, which was then centrifuged at 3400 rpm for 20 min at 15°C. 
 
Instrumental analysis 
Apparatus 
Analysis of THPI and PI was performed using a Varian Model 212-LC Binary Gradient LC 
system (Les Ulis, France) connected to a Prostar model 410 autosampler (Varian, Les Ulis, 
France) and coupled to a Model 1200 L quadrupole MS (Varian, Les Ulis, France) operating in 
APCI mode. The APCI interface was operated in the negative ion mode and its specific APCI-
MS parameters were manually optimized and identical for both analytes.  
9 
 
Analytical conditions 
The compounds were separated using a C18 Zorbax Eclipse Plus column (4.6 x 150 mm, 3.5 µm) 
from Agilent (Morges, Switzerland). The temperature of the column was maintained at 30oC. The 
mobile phase consisted of: eluent A composed of 90% water and 10% acetonitrile (9:1), and 
eluent B of 10% water and 90% acetonitrile (1:9). For THPI analysis, elution was performed in 
14 min using a solvent gradient, at a flow rate of 0.8 mL/min. The following solvent program was 
used: 90% eluent A for 3 min, followed by a linear gradient to 5% eluent A from 3 to 10 min, 
maintained at 5% eluent A from 10-13 min before returning to initial conditions of 90% eluent A 
in 1 min. For PI analysis, elution was performed in 21 min at a flow rate of 0.8 mL/min using the 
following sequence: 90% eluent A for 15 min and then ramping to 5% eluent A in 30 sec for a 4 
min clean up at 5% eluent A prior to returning to initial conditions in 1 min. Several gradients 
were tested to obtain a chromatographic run as short as possible while allowing separation from 
interfering peaks and aiming at the best sensitivity for both compounds. In addition, we opted for 
12-min re-equilibration period between runs. The samples were kept at 8°C on the injection tray 
and 10 µL were injected. 
 
Once analytes and mobile phase reached the ionization source, they were subjected to a needle 
voltage of -10 µA, a spray shield voltage of -600 V and a spray chamber temperature of 60°C. 
Then, air as nebulizer gas was set to a pressure of 60 psi followed by vaporizing gas of 12 psi 
with a temperature of 500°C. Lastly, a drying gas (N2) was set to 35 psi with a temperature of 
350°C in the hexapole before product ions were transmitted in quadrupoles. In the collision cell, 
ions were fragmented with argon at a pressure of 1.45 mTorr on average. Collision energy (CE) 
was 19.5 V for THPI, 22.5 V for THPI-d and 5V for PI. The precursor and product ion analyzed 
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were m/z 149.4/95.6 for THPI, m/z 156.1/95.6 for THPI-d and m/z 145.8/145.8 for PI (PI not 
fragmented). Fragment ions were then detected by the electron multiplier voltage at 1455 V. 
Identification and quantification were performed in multiple reaction monitoring (MRM) mode. 
 
Quantification of THPI and PI 
The quantification of THPI and PI was obtained from standard calibration curves in urine or in 
plasma. These latter curves were established by plotting the response factors as a function of the 
concentrations levels, over a maximum range of 1 to 250 µg/L for both analytes depending on the 
matrix. The response factors corresponded to the peak-area ratios of each compound ion to the 
internal standard ion. 
 
Methods validation 
Since no commercial quality control samples was available for THPI and PI, the criteria used to 
validate the four methods were specificity, sensitivity, linearity, intra- and inter-day precision, 
accuracy, recovery and stability. 
 
Specificity 
Specificity was determined by analyzing ten urine and plasma samples from unexposed 
individuals and by verifying the absence of endogenous interferences on the chromatograms for 
these blank matrices. 
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Sensitivity 
Sensitivity of the analytical methods was estimated by the limit of detection (LOD) and the limit 
of quantification (LOQ). LOD was calculated from calibration curves (6 for urines and 10 for 
plasma) using the definition: 
y – yB = 3sB 
where y was the response factor, yB was the blank response or the intercept of regression line, and 
sB the standard deviation of the blank [19]. The LOD of each compound was determined for each 
calibration curve, and then means were calculated and considered as LODs. As for the LOQ, it 
was defined as equivalent to 3.3 times the LOD. 
 
Linearity 
Linearity of the methods was evaluated by calculating regression parameters of calibration curves 
in urine or in plasma for both compounds by the least square fit method. Results were expressed 
using the average coefficient of determination (R
2
) of eight calibration curves in urine and ten 
calibration curves in plasma over the studied ranges. 
 
Intra- and inter-day precision and accuracy 
Intra-day and inter-day variations were assessed by the precision and the accuracy of replicates of 
three different levels of spiking of blank urine with THPI and PI and of five levels of spiking of 
blank plasma. The intra-day variation was measured by the repeatability of each level prepared in 
two replicates and analyzed during the same day (n = 6), and the inter-day variation was assessed 
by the repeatability of each level (daily prepared) on eight consecutive days for urine (n = 8) and 
twenty consecutive days for plasma (n = 20). Precision was expressed as a percentage of relative 
standard deviation (% RSD) and defined as the ratio of standard deviation to mean of the 
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response factor for each level of spiking multiplied by 100. Accuracy (expressed in percentage) 
was estimated by the following equation: 
( )average measured amount - known spiking amount
known spiking amount
  100×  
 
Recovery 
To determine the recovery of each compound in both studied matrices after extraction, the ratio 
of measured amount of THPI and PI in extracts to the theoretical spiked amount in blank urine or 
plasma was calculated for each level. The recovery was expressed as a percentage. 
 
Stability 
To establish stability of compounds in urine and in plasma, pools of blank urine or plasma were 
spiked at different concentration levels defined above for calibration curves, and then separated 
in aliquots and stored at -20°C. Every day, over an 8-day period for urine and a 20-day period for 
plasma, an aliquot of each concentration level was thawed and analyzed. 
 
The stability of urinary samples from volunteers exposed to captan or folpet was also tested. Two 
samples thawed and analyzed for THPI or PI in a given run were kept at 4°C and processed and 
reanalyzed during the following run. 
 
Application of the methods 
The use of the analytical methods for the quantification of THPI and PI in human plasma and 
urine samples of exposed individuals was then tested. THPI and PI concentrations were measured 
in the urine and plasma collected repeatedly over a 96- and 72-h period respectively following an 
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oral and dermal exposure to captan in ten volunteers. These metabolites were also measured in 
urine samples repeatedly collected over a typical workweek in applicators exposed to captan and 
folpet. 
 
The Permanent Ethical Committee of Clinical Research of the Faculty of Biology and Medicine 
of the University of Lausanne and of the Research Ethical Committee of the Faculty of Medicine 
of the University of Montreal approved the protocol, and all participants gave written informed 
consent, and were acquainted with the risks of participating and their right to withdraw from the 
study at all time. 
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Results and discussion 
 
The analytical methods developed allowed to accurately, specifically and sensitively quantify 
THPI and PI in both human urine and plasma by LC/APCI-MS/MS. 
 
Methods development 
In developing the methods, several tests were performed to determine the best sample treatment 
and analysis conditions for a precise, reliable, easy and quick procedure. First, liquid-liquid 
extraction of THPI and PI analytes in plasma and urine using acetonitrile or dichloromethane 
solvents were tested, but solid phase extraction (SPE) was shown to provide noticeably improved 
processing recoveries and reproducibility, less interfering peaks on PI chromatograms and 
simpler and faster processing of samples (data not shown). Once chromatographic conditions 
were properly set, it was also evaluated whether acid or enzymatic hydrolyses were needed to 
deconjugate metabolites in human plasma and urine since interactions between thiol- and non-
thiol-containing proteins and captan or folpet were reported [20]. This procedure was found 
unnecessary and even lead to some degradation of THPI and PI, as assessed on urine samples 
from volunteers orally exposed to captan or folpet after incubation at 37
o
C with β-
glucuronidase/arylsulfatase or heating at 100oC in the presence of HCl 12 N during different time 
periods (2, 4, 6 and 16 h) (data not shown). Analysis was thus performed without any hydrolysis 
step.  
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For LC-MS separation and quantification of THPI and PI, different polar solvents and mixed 
solutions were also tested as mobile phases. Acetonitrile was finally selected instead of methanol 
because sensitivity was significantly increased and peak separation was better defined for PI, 
which fragmentation was not achieved. Several analytical columns were further tested (i.e., 
Luna
®
 C18, Luna
®
 NH2 columns from Phenomenex, Spherisorb ODS2 from Waters and C18 
Zorbax Eclipse Plus from Agilent), but since THPI is a weak base (pKa = 9.65), PI a weak acid 
(pKa = 6.96) and both are polar molecules, the C18 Zorbax Eclipse Plus column was found to be 
the most appropriate to retain these two metabolites and the internal standard. Thus, short 
retention times were obtained with a very good repeatability for all analytes: 5.8 minutes for 
THPI, 8.7 minutes for PI and 5.6 minutes for THPI-d. In addition, electrospray ionization (ESI) 
was initially selected prior to APCI mode, but no peak was observed for PI and the sensitivity for 
THPI was poor. 
 
Chromatography 
Figures 2-5 show chromatograms of plasma and urine samples of non-occupationally exposed 
individuals along with blank plasma and urine samples spiked with different concentrations of 
THPI or PI following treatment of samples by solid phase extraction (see Materials and 
Methods). Typical chromatograms of plasma and urine samples of volunteers treated with captan 
and folpet are also represented. For THPI and THPI-d quantification, clean chromatograms were 
observed with limited background interference, implying that clean up treatment of samples was 
efficient and analytical conditions were suitable for the methods to be specific. Moreover, the 
formation of fragment ions (Fig. 2 and Fig. 4) facilitated identification of both analytes, which 
were also used for quantification. On the other hand, for PI quantification, chromatograms 
contained several peaks other than those of PI and THPI-d used as an internal standard (Fig. 4 
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and 5) and fragmentation of PI was not achieved such that only the parent ion was quantified. To 
separate interference peaks from that of PI, an optimization of LC separation was performed and 
a high percentage of water in the eluent phase was needed. Different analytical conditions were 
thus required to analyze PI and THPI. However, both conditions were accurate for analyzing 
THPI-d, although THPI elution conditions provided narrower peaks and better sensitivity. 
 
Analysis of chromatograms of plasma and urine samples of individuals of the general population 
non-occupationally exposed to captan or folpet also shows the presence of a baseline level of 
exposure in some cases. As illustrated in Fig. 2b, Fig. 4a and Fig. 5a, THPI and PI was detectable 
in some urine samples of non exposed individuals and also in plasma for PI, but in very small 
concentrations (about 10 nmol/L for THPI in urine, and on average 5.5 nmol/L in plasma and 4 
nmol/L in urine for PI). Barr et al. [3] detected also THPI in 43% of plasma samples from 70 
non-exposed women living in an urban environment, and 51% of samples contained PI. 
 
Chromatograms of plasma and urine samples of volunteers orally exposed to captan and folpet, 
with and without spiking with reference standards, were further compared (Fig. 2c, Fig. 3c, Fig. 
4c and Fig. 5b). For both THPI and PI, no chromatographic differences were noted between 
spiked and non-spiked matrices; retention times were exactly the same, peaks had the same shape 
and no interference peaks appeared. These methods thus appeared specific for the biomonitoring 
of exposure in individuals. 
 
Quantification 
To quantify THPI or PI, peak area ratio of the analyte to the internal standard was calculated for 
the various concentration levels of the calibration curves; this adjustment by internal standard 
17 
peak area allowed to account for analyte loss in extraction and analysis, as well as eliminate 
potential variations due to the apparatus and reduce errors associated with measurements. The use 
of a deuterated form of THPI as an internal standard also provided a molecule structurally related 
to captan and folpet biomarkers, but distinguishable by its mass. This increased the precision and 
specificity of the methods, even for PI, which had several similarities with THPI despite its 
aromatic core. 
 
Methods validation 
The methods developed were evaluated using the following criteria described in Materials and 
Methods section: sensitivity, linearity, intra- and inter-day precision and accuracy, recovery and 
stability.  
 
Table 1 presents the estimated LODs and LOQs of THPI and PI in urine and plasma. They were 
established within the concentration range of 0.5 to 50 µg/L for THPI and PI in urine and 1 to 
100 µg/L for THPI and PI in plasma. LOD was 0.58 and 1.47 µg/Lfor THPI in urine and plasma 
respectively, and corresponding LOQ was 1.90 and 4.87 µg/L. In comparison, LOD was 1.14 and 
2.17 µg/L for PI in urine and in plasma respectively, and LOQ was 3.75 and 7.19 µg/L. The 
sensitivity was however better for THPI than PI given that the latter molecule could not be 
fragmented in MS and elution conditions had to be adjusted to provide a better separation of PI 
from interfering peaks on the chromatograms. The developed methods for both THPI and PI were 
at least as sensitive as those published in the literature (Table 2). For instance, our values were 
comparable to the method of Barr et al. [3] and Hines et al. [6]. 
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As for the linearity of standard calibration curves in methanol, plasma and urine, they are 
displayed in Fig. 6 for THPI and in Fig. 7 for PI. All curves were linear over the studied 
concentration range for THPI and PI, and resulted in a coefficient of determination greater than 
0.99. Furthermore, matrix effects were not tested per se since APCI mode is less susceptible than 
ESI mode [18; 20; 21]. However, for THPI, calibration curves prepared in methanol had similar 
slopes to those prepared in urine, indicating the absence of urinary matrix effect for this analyte. 
On the other hand, matrix effects were obvious for calibration curves of THPI and PI prepared in 
plasma as well as those of PI in urine. Calibration was thus performed using standard curves in 
plasma and urine for both analytes (with more spiking levels for plasma given the observed wider 
concentration range of THPI and PI in volunteers and more calibration curves for validation 
given plasma matrix effects).  
 
Precision and accuracy of the methods of analysis of THPI and PI in plasma and urine are further 
presented in Table 3. Intra-day and inter-day precision and accuracy were satisfactory with % 
relative standard deviation (RSD) less than 15% (except for the first urinary level of THPI and 
PI) and % relative error (RE) of less than 20%. 
 
Table 3 gives also an overview of recoveries of THPI and PI in spiked plasma and urine samples, 
after solid-phase extraction and processing. They were quite good for both compounds in these 
matrices, except for PI at low concentrations given matrix effects. The mean (± SD) recoveries of 
THPI (i.e. all spiked sample results combined) were 90.4 ± 9.9% (n = 20) in urine and 90.9 ± 
6.7% (n = 100) in plasma; corresponding values for PI were 72.9 ± 18.6% (n = 20) in urine and 
79.6 ± 11.3% (n = 100) in plasma (as plasma was not collected for workers, more runs with urine 
samples were performed than with plasma samples). These results were similar to those reported 
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in the literature. Indeed, several authors found a recovery rate of THPI in human urine varying 
between 82 to 90% over the same concentration range [6-10]; Barr et al. [3] obtained a recovery 
rate of 91% for THPI in human plasma, and of 89% for PI in human plasma like Canal-Raffin et 
al. [4] in rat plasma (Table 2). To our knowledge, no published methods are available for the 
analysis of PI in human urine. 
 
Furthermore, stability of THPI and PI standards in plasma and urine samples kept at -20
o
C was 
tested over an 8-day period for urine and over a 20-day period for plasma. Since intra-day 
precision and accuracy values were similar to those of inter-day precision and accuracy, both 
analytes were thus considered stable in plasma and urine over the studied period (Table 3). The 
same observations were made by Canal-Raffin et al. [4] for the stability of PI in rat plasma, and 
Barr et al. [3] reported that THPI and PI in human plasma were stable over a period of four 
months. 
 
THPI and PI in urine samples of volunteers treated with captan or folpet were also relatively 
stable, when kept at 4°C and re-analyzed in the following analytical run. A coefficient of 
variation ranging between 2.98 and 6.57% were obtained for THPI (n = 12) and between 1.51 and 
7.56% for PI (n = 12). The same tests could not be performed with plasma samples because of the 
limited amount of matrix available. 
 
Application 
With the developed analytical methods, it was verified that THPI and PI could easily be 
quantified in urine and plasma of volunteers exposed to captan or folpet at 1 mg/kg of body 
weight by oral route and at 10 mg/kg of body weight by dermal route; Fig. 8 presents the mean 
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concentration-time profiles of THPI and PI in urine and plasma following both an oral and 
dermal exposure. The methods were found to be sensitive enough to document the toxicokinetics 
of THPI in human plasma and urine at equivalently realistic daily absorbed doses in workers. 
 
On the other hand, PI concentrations in plasma and urine were much lower than those of THPI 
for the same exposure dose. When PI was administered to rats, Chasseaud et al. [23] observed 
that about 80% of the dose was metabolized and excreted in urine as phthalamic acid and 7% as 
phthalic acid, showing that PI is a minor metabolite of folpet in urine. Moreover, Chasseaud et al. 
[24] established that when labelled 
14
C-folpet was administered to rats, 80% was recovered in the 
urine as phthalamic acid, and Canal-Raffin et al. [4] observed that PI was rapidly hydrolyzed to 
phthalamic acid in plasma following an intratracheal administration of folpet in rats. PI is 
however more specific to folpet exposure than the phthalic acid, which is also a phthalate 
metabolite [25; 26].  
 
Table 4 presents pre-and post-shift levels of THPI and PI in urine during the course of a 
workweek in applicators exposed to captan and folpet, respectively. This table shows that the 
metabolites were easily measured in the urine of workers following a one-day exposure episode, 
as compared to pre-seasonal measurements or, in the case of folpet, baseline values observed a 
few days after application. According to our results, THPI appears as a sensitive and specific 
biomarker of captan exposure in exposed individuals; PI can also be considered as a specific 
biomarker of folpet exposure but is less sensitive than THPI. 
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Conclusion 
 
The LC/APCI-MS/MS methods proved to be simple and reliable to quantify THPI and PI in 
human plasma and urine. Their good sensitivity, specificity, linearity, accuracy and precision 
were also validated and found at least equivalent to methods reported in the literature. These 
methods thus appear suitable for the biomonitoring of exposure to captan and folpet in exposed 
individuals. 
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Table 1 
Performance parameters of the methods 
 
Analyte Matrix 
LOD
a
 
(mean ± SD) 
LOQ
b
 
(mean ± SD) 
Working range 
  (µg/L) (µg/L) (µg/L) 
THPI Urine (n = 6) 0.58 ± 0.28 1.9 ± 0.92 0.5 – 50 
 Plasma (n = 10) 1.47 ± 0.69 4.87± 2.28 1 – 100 
PI Urine (n = 6) 1.14 ± 0.22 3.75 ± 0.72 0.5 – 50 
 Plasma (n = 10) 2.17 ± 0.39 7.19 ± 1.29 1 – 100 
 
a Limit of detection (LOD) was calculated from calibration curves (6 for urine and 10 for plasma) using the definition: y – yB = 3sB, where y was the 
response factor, yB was the blank response or the intercept of regression line, and sB the standard deviation of the blank [19]. The LOD of each 
compound was determined for each calibration curve, and then means were calculated and considered as LODs. 
b
 Limit of quantification (LOQ) was defined as 3.3 times the detection limit. 
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Table 2 
Comparison of performance parameters of available analytical methods for THPI and PI analysis in human plasma and urine. 
Methods 
Detection 
technique 
LODa Spiking  
Recovery 
(%) 
(mean ± SD) 
Extraction type 
THPI in urine      
Shoen et al. [9] GC/NPD/MS 165 nmol/L 198 nmol/L 
331 nmol/L 
3307 nmol/L 
82 ± 10.5 (n = 9) 
87 ± 5.2 (n = 5) 
86 ± 5.8 (n = 5) 
Solvent extraction 
van Welie et al. [10] GC/CI/MS 17.9 nmol/L 17.9 – 360 nmol/L 54 ± 5.0 (n = 4) Solvent extraction 
Krieger and Thongsinthusak [7] GC/NPD/MS 33.1 – 66.1 nmol/L 66.1 nmol added 
661 nmol added 
90 
95 
Solvent extraction 
Krieger and Dinoff [8] GC/ECD/MS 33.1 nmol/L 33.1 – 13230 nmol/L 78 ± 5.0 Solvent extraction 
Hines et al. [6] GC/MS 11.2 nmol/L 33.1 – 265 nmol/L 86 ± 9.1 (n = 179) Solvent extraction 
Our study LC/APCI-MS/MS 3.82 nmol/L 3.31 – 33.1 pmol added 94.3 ± 7.2 (n = 24) Solid phase extraction 
 
THPI in plasma 
  
  
 
Barr et al. [3] GC/HR/MS 1 pg/g 1.58 – 2646 nmol/L 91 ± 8.0 (n = 6) Solid phase extraction 
Our study LC/APCI-MS/MS 9.76 nmol/L 16.5 – 827 pmol added 90.9 ± 6.7 (n = 100) Solid phase extraction 
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Methods 
Detection 
technique 
LODa Spiking  
Recovery 
(%) 
(mean ± SD) 
Extraction type 
PI in Plasma 
Barr et al. [3] GC/HR/MS 20 pg/g 1.58 – 2646 nmol/L 89 ± 6.0 (n = 6) Solid phase extraction 
Canal-Raffin et al. [4] HPLC-UV/DAD 33.1 nmol/L 67.9 – 679.7 nmol/L 90 ± 6.9 (n = 12) Solid phase extraction 
Our study LC/APCI-MS/MS 7.72 nmol/L 17.0 – 850 pmol added 79.6 ± 11.3 (n = 100) Solid phase extraction 
n: Number of samples. 
GC/CI/MS: gas chromatograph equipped with a chemical ionization and a mass spectrometer; GC/ECD/MS: gas chromatograph with an electrolytic 
conductivity detector and a mass spectrometer; GC/HR/MS: gas chromatography-high resolution mass spectrometry; GC/NPD\MS: gas 
chromatograph equipped with nitrogen-phosphorus detector and a mass spectrometer; HPLC-UV/DAD: high-performance liquid chromatography 
with ultraviolet diode array; LC/APCI-MS/MS: liquid chromatography with a mass spectrometer and atmospheric pressure chemical ionization. 
a
 Limit of detection (LOD) was defined as the concentration with a signal-to-noise ratio of at least 3, except for Barr et al. [3] and our study, where the 
LOD was calculated as 3s0 where s0 was estimated as the y-intercept of a linear regression analysis of a plot of the absolute standard deviation versus 
the concentration. 
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Table 3 
 
Recovery, intra- and inter-day precision and accuracy of THPI and PI at three different spiking levels (pmol added) of blank human urine and at five 
different spiking levels (pmol added) of blank  human plasma. 
             
      Intra-day variation
a
  Inter-day variation
b
 
Analytes Matrix 
Amount 
added 
(pmol)
c 
Recovery
d 
(%) 
RSD
e 
(%) 
 
Amount found
f 
(pmol) 
(mean ± SD
g
) 
Precision 
(% RSD
e
) 
Accuracy
h
 
(%) 
 
Amount found
f
 
(pmol) 
(mean ± SD
g
) 
Precision 
(% RSD
e
) 
Accuracy
h
 
(%) 
THPI Urine  (n = 8)   (n = 6)    (n = 8)   
  3.31 103.6 15.06  3.58 ± 0.42 11.74 8.13  3.66 ± 0.61 16.69 10.55 
  13.2 87.35 13.35  11.50 ± 0.38 3.28 –13.07  11.56 ± 1.54 13.35 –12.65 
  33.1 93.47 9.68  31.58 ± 1.46 4.62 –4.52  30.92 ± 2.99 9.67 –6.53 
             
 Plasma  (n = 20)   (n = 10)    (n = 20)   
  16.5 83.02 13.67  13.78 ± 0.97 7.03 –16.71  13.73 ± 1.88 13.67 –16.98 
  33.1 82.92 13.28  27.46 ± 2.75 10.00 –16.98  28.28 ± 4.44 15.70 –14.51 
  165 93.44 10.81  155.05 ± 9.07 5.85 –6.25  154.53 ± 16.70 10.81 –6.56 
  331 95.32 7.99  316.14 ± 19.23 6.08 –4.42  315.30 ± 25.18 7.99 –4.67 
  827 99.49 7.77  818.61 ± 38.07 4.65 –1.01  822.72 ± 63.95 7.77 –0.51 
30 
             
PI Urine  (n = 8)   (n = 6)    (n = 8)   
  3.40 42.65 6.54  1.42 ± 0.38 21.92 ----- 
i
  1.24 ± 0.36 28.92 ----- 
i
 
  13.6 82.32 15.4  12.06 ± 0.36 3.03 –11.26  12.9 ± 1.06 8.19 –4.51 
  34.0 88.73 14.29  31.01 ± 7.09 14.4 -8.73  33.89 ± 8.18 8.18 –0.26 
             
 Plasma  (n = 20)   (n = 10)    (n = 20)   
  17.0 67.3 15.2  11.42 ± 0.84 7.35 ----- 
i
  9.80 ± 0.85 8.67 ----- 
i
 
  34.0 73.4 14.3  25.24 ± 2.01 9.41 ----- i  25.82 ± 2.23 8.65 ----- i 
  170 87.3 13.5  151.84 ± 14.30 11.41 –10.64  148.38 ± 17.16 11.56 –12.68 
  340 85.1 10.1  277.48 ± 12.96 4.67 –18.35  277.60 ± 15.67 5.64 –18.31 
  850 90.4 12.8  800.23 ± 74.62 9.32 –5.81  748.81 ± 96.99 12.95 –11.86 
 
n: Number of samples for each spiking level. 
a Average variation between N replicates of the same level of spiking prepared and analyzed the same day. 
b
 Average variation between N replicates of the same level of spiking prepared and analyzed on different days over an 8-day period for urine and a 
20-day period for plasma. 
c
 Amount of THPI or PI (expressed in pmol) added to blank urine or plasma at the different concentration levels. 
d
 Percent recovery of THPI or PI amounts (different levels) added to blank urine or plasma samples and processed as described in Materials and 
Methods. 
31 
e Precision or RSD: relative standard deviation for N replicates calculated as (SD/mean) x 100. 
f
 Recovered amount of THPI or PI after sample processing and calculated from calibration curves. 
g
 SD: standard deviation of N replicates. 
h
 Accuracy, or percent relative error, calculated using the following equation: (amount found – amount added)/amount added x 100. 
i 
These accuracy values are not reported since matrix effects were apparent for PI at these low spiking levels contrary to THPI-d used as an internal 
standard. 
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Table 4 
Concentrations of THPI and PI in applicators exposed to captan and folpet, respectively, during the course of a typical workweek along with pre-
seasonal concentrations 
Metabolite 
analyzed 
Applicator 
Concentration (nmol/L) 
Pre-seasonal  Workday 1
a
 Workday 2 Workday 3 Workday 4 Workday 5 
Pre-shift Post-shift Pre-shift Post-shift Pre-shift Post-shift Pre-shift Post-shift Pre-shift Post-shift 
THPI             
 Applicator 1 <LOD
b
 4.24 14.17 23.61 43.18 10.01 11.27 12.07 12.93 10.62 5.83 
 Applicator 2 <LOD <LOD 21.53 54.17 43.09 43.71 17.55 15.38 14.16 8.55 10.17 
             
PI
 
            
 Applicator 1 <LOD
c
 16.95 11.41 8.42 17.01 8.87 <LOD <LOD <LOD <LOD 17.74 
 Applicator 2 ≈LOD 21.71 42.43 42.61 31.51 33.97 26.19 ≈LOD <LOD 13.86 21.70 
 Applicator 3 <LOD <LOD 13.71 15.06 <LOD <LOD <LOD <LOD <LOD 8.96 ≈LOD 
a
 Captan and folpet were sprayed on workday 1 only. 
b
 LOD of THPI in urine = 3.82 nmol/L. 
c LOD of PI in urine = 7.72 nmol/L. 
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Figure captions 
 
Fig. 1  Chemical structures of (a) captan and its metabolite THPI and (b) folpet and its 
metabolite PI. 
 
Fig. 2 Representative chromatograms of THPI and THPI-d in human urine: (a) blank urine 
spiked with 10 µg/L of THPI (1) and 75 µg /L of THPI-d (2); (b) urine from an unexposed 
subject (3) and blank urine spiked with 1 µg /L of THPI (4); (c) blank urine spiked with 10 µg/L 
of THPI (1) and 75 µg /L of THPI-d (2) along with a urine sample of a volunteer exposed orally 
to captan (5) spiked with 75 µg /L of THPI-d (6). Chemical structures of THPI, THPI-d and their 
measured ion fragment are also represented. 
 
Fig. 3 Representative chromatograms of PI and THPI-d in human urine: (a) blank urine spiked 
with 1 µg /L of PI (1) and 26.5 µg /L of THPI-d (2); (b) urine from an unexposed subject (3) and 
blank urine spiked with 10 µg /L of PI (4), 50 µg /L of PI (5) and 100 µg /L (6); (c) blank urine 
spiked with 1 µg /L of PI (1) and 26.5 µg /L of THPI-d (2) along with a urine sample of a 
volunteer exposed orally to folpet (7) spiked with 26.5 µg /L of THPI-d (8). Chemical structures 
of PI, THPI-d and its measured ion fragment are also represented. 
 
Fig. 4 Representative chromatograms of THPI and THPI-d in human plasma: (a) blank plasma 
spiked with 50 µg /L of THPI (1) and 79.5 µg /L of THPI-d (2); (b) plasma sample from an 
unexposed subject (3) and blank plasma spiked with 1 µg /L of THPI (4); (c) blank plasma spiked 
with 50 µg /L of THPI (1) and 79.5 µg /L of THPI-d (2) along with a plasma sample of a 
volunteer exposed orally to captan (5) spiked with 79.5 µg /L of THPI-d (6). 
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Fig. 5 Representative chromatograms of PI and THPI-d in human plasma: (a) plasma sample 
from an unexposed subject (1) spiked with 79.5 µg /L of THPI-d (2) and blank plasma spiked 
with 1 µg /L of PI (3) and 79.5 µg /L of THPI-d (4); (b) plasma from an unexposed subject (5) 
and blank plasma spiked with 10 µg /L of PI (6); (c) blank plasma spiked with 1 µg /L of PI (3) 
and 79.5 µg /L of THPI-d (4) along with a plasma sample of a volunteer exposed orally to folpet 
(7) spiked with 79.5 µg /L of THPI-d (8). 
 
Fig. 6 Calibration curves of THPI over the concentration range of 0.003 to 0.66 µmol/L (0.5 to 
100 µg/L) prepared in methanol (▼), blank urine (○) and blank plasma (●). The linearity of 
curves is described by the coefficient of determination (R2) and equations are presented. 
 
Fig. 7 Calibration curves of PI over the concentration range of 0.5 to 50 µg/L prepared in 
methanol (▼), blank urine (○) and blank plasma (●). The linearity of curves is described by the 
coefficient of determination (R
2
) and equations are presented. 
 
Fig. 8 (a) Concentration-time profiles of THPI (mean ± SD) in volunteers exposed to captan 
orally (1 mg/kg) or dermally (10 mg/kg) and (b) concentration-time profiles of PI (mean ± SD) in 
volunteers exposed orally and dermally to folpet (1 and 10 mg/kg, respectively).  (-●-) Urinary 
excretion profile following oral exposure; (-○-) urinary excretion profile following dermal 
exposure; (-▼-) plasma profile following oral exposure; (-∆-) plasma profile following dermal 
exposure. 
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